These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript. Helbig G; Soja A; Świderska A; Hus M; Kyrcz-Krzemień S Leuk Lymphoma; 2016; 57(3):708-10. PubMed ID: 26430910 [No Abstract] [Full Text] [Related]
4. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia. Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057 [No Abstract] [Full Text] [Related]
5. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome. Helbig G; Kyrcz-Krzemień S Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127 [No Abstract] [Full Text] [Related]
6. The results of imatinib therapy for patients with primary eosinophilic disorders. Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506 [No Abstract] [Full Text] [Related]
7. Detection of FIP1L1-PDGFRA fusion by FISH. Ma ES; Wong KF; Wong CL; Siu LL Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982 [No Abstract] [Full Text] [Related]
8. Lymphomatoid papulosis associated with myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement: Successful imatinib treatment in two cases. Bellani V; Croci GA; Bucelli C; Maronese CA; Alberti S; Iurlo A; Cattaneo D J Dermatol; 2023 Oct; 50(10):1330-1334. PubMed ID: 37248740 [TBL] [Abstract][Full Text] [Related]
9. Successful treatment with imatinib of lymphomatoid papulosis associated with myeloproliferative hypereosinophilic syndrome with PDGFRA rearrangement. Torres-Navarro I; Navarro-Mira MÁ; de Unamuno-Bustos B; Botella-Estrada R J Dtsch Dermatol Ges; 2020 Apr; 18(4):378-380. PubMed ID: 32291914 [No Abstract] [Full Text] [Related]
10. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib. Pitini V; Sturniolo G; Cavallari V; Arrigo C Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645 [No Abstract] [Full Text] [Related]
11. [FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy]. Nemchenko IS; Khoroshko ND; Turkina AG; Sokolova MA; Kokhno AV; Semenova EA; Zakharova AV Ter Arkh; 2005; 77(7):90-2. PubMed ID: 16116920 [No Abstract] [Full Text] [Related]
12. Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFRA positive myeloid neoplasm. Blum S; Dunet V; Comoli P; Tirefort Y; Chalandon Y; Opota O; Comte D; Spertini O; Livio F; Brouland JP; Du Pasquier R Leuk Lymphoma; 2020 Sep; 61(9):2226-2229. PubMed ID: 32364409 [No Abstract] [Full Text] [Related]
13. [Identification of clonal proliferation of T cell and FIP1L1-PDGFRalpha fusion gene in hypereosinophilic syndrome associated with lymphomatoid papulosis which showed rapid and complete response to the treatment with imatinib]. Fujimi A; Kanisawa Y; Kikuchi S; Okuda T; Sato Y; Doi T; Ohta H; Umeda I; Nobuoka A Nihon Naika Gakkai Zasshi; 2007 Dec; 96(12):2794-7. PubMed ID: 18203417 [No Abstract] [Full Text] [Related]
14. The hypereosinophilic syndrome: idiopathic or not, that is the question. Cools J Haematologica; 2005 May; 90(5):582-4. PubMed ID: 15921372 [No Abstract] [Full Text] [Related]
15. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement. Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119 [TBL] [Abstract][Full Text] [Related]
16. Imatinib for the treatment of hypereosinophilic syndromes. Helbig G Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368 [TBL] [Abstract][Full Text] [Related]
17. Response to imatinib mesylate in patients with hypereosinophilic syndrome. Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436 [TBL] [Abstract][Full Text] [Related]